A Simple HPLC-UV Method for Ivosidenib Determination in Human Plasma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Simple HPLC-UV Method for Ivosidenib Determination in Human Plasma
Authors
Keywords
-
Journal
JOURNAL OF CHROMATOGRAPHIC SCIENCE
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2023-10-04
DOI
10.1093/chromsci/bmad082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
- (2022) Pau Montesinos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1 ‐mutant advanced hematologic malignancies
- (2021) Xuemin Jiang et al. CTS-Clinical and Translational Science
- Quantitation of ivosidenib in human plasma via LC–MS/MS and its application in clinical trials
- (2021) Feng Yin et al. Bioanalysis
- Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant IDH1 for Treatment of IDH1-Mutant Malignancies
- (2021) Yue Chen et al. DRUG METABOLISM AND DISPOSITION
- The implications of IDH mutations for cancer development and therapy
- (2021) Christopher J. Pirozzi et al. Nature Reviews Clinical Oncology
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- (2021) Andrew X. Zhu et al. JAMA Oncology
- Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib
- (2021) Benjamin M Ellingson et al. NEURO-ONCOLOGY
- Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
- (2020) Bin Fan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
- (2020) William D. Tap et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects
- (2019) David Dai et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mice plasma: Application to a pharmacokinetic study
- (2019) Ashok Zakkula et al. BIOMEDICAL CHROMATOGRAPHY
- Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 vs. Neonatal Cytochrome P450 3A7
- (2018) Malika P. Godamudunage et al. DRUG METABOLISM AND DISPOSITION
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis
- (2016) Lena M. Biehl et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Drug Interactions between Nine Antifungal Agents and Drugs Metabolized by Human Cytochromes P450
- (2015) Toshiro Niwa et al. CURRENT DRUG METABOLISM
- DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
- (2014) A P Im et al. LEUKEMIA
- Potential application ofIDH1andIDH2mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis
- (2012) Kuang-Guo Zhou et al. LEUKEMIA & LYMPHOMA
- Acute Myeloid Leukemia WithIDH1orIDH2Mutation
- (2010) Keyur P. Patel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More